Enhance Skin Products (EHSK) 10-Q 2010 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended January 31, 2010

OR

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to _____________

Commission File Number 000-52755

ENHANCE SKIN PRODUCTS INC.

(Exact name of registrant as specified in its charter)

Nevada	84-1724410
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

695 South Colorado Boulevard, Suite 400, Denver, Colorado 80246

(Address of principal executive offices)                      (Zip Code)

Registrant's telephone number, including area code:    416-644-8318

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the  preceding 12 months (or for such  shorter  period that the  registrant  was required  to file  such  reports),  and  (2) has  been  subject  to such  filing requirements for the past 90 days.     Yes x    No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes o     No x

Number of shares outstanding of the registrant's class of common stock as of March 14, 2009: 49,250,000

1

FORWARD-LOOKING STATEMENTS

THIS QUARTERLY REPORT ON FORM 10-Q CONTAINS PREDICTIONS, PROJECTIONS AND OTHER STATEMENTS ABOUT THE FUTURE THAT ARE INTENDED TO BE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (COLLECTIVELY, "FORWARD-LOOKING STATEMENTS"). FORWARD LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES. A NUMBER OF IMPORTANT FACTORS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS. IN ASSESSING FORWARD-LOOKING STATEMENTS CONTAINED IN THIS QUARTERLY REPORT ON FORM 10-Q, READERS ARE URGED TO READ CAREFULLY ALL CAUTIONARY STATEMENTS- INCLUDING THOSE CONTAINED IN OTHER SECTIONS OF THIS QUARTERLY REPORT ON FORM 10-Q. AMONG SAID RISKS AND UNCERTAINTIES IS THE RISK THAT THE COMPANY WILL NOT SUCCESSFULLY EXECUTE ITS BUSINESS PLAN, THAT ITS MANAGEMENT IS ADEQ UATE TO CARRY OUT ITS BUSINESS PLAN AND THAT THERE WILL BE ADEQUATE CAPITAL OR THEY MAY BE UNSUCCESSUFL FOR TECHNICAL, ECONOMIC OR OTHER REASONS.

PART I - FINANCIAL INFORMATION

ITEM 1.   Financial Statements.

	Page Number
Balance Sheets	3
Statements of Operations	4
Statement of Stockholder's Equity	5
Statements of Cash Flows	6
Notes to the Financial Statements	7

2

ENHANCE SKIN PRODUCTS INC.
formerly Zeezoo Software Corp.
CONSOLIDATED CONDENSED BALANCE SHEETS
	(Unaudited)
	January 31			April 30
	2010			2009
ASSETS
Current
Cash	$	4,923		$	361,606
Accounts receivable		140			-
Sales tax receivable		1,131			8,609
Prepaids & deposits		1,121			19,228
Inventory		79,253			43,613
Total current assets		86,568			433,056
Other assets
Patent applications		52,673			43,166
Trademarks		45,053			44,115
Total other assets		97,726			87,281
Total assets	$	184,294		$	520,337
LIABILITIES AND STOCKHOLDER'S EQUITY
Current liabilities
Accounts payable and accrued liabilities	$	84,726		$	16,504
Accounts payable to related party		158,064			259
Total current liabilities		242,790			16,763
Stockholders equity (deficit)
Authorized:
100,000,000 common shares per value $0.001
Issued and outstanding 49,250,000 as of
January 31, 2010 and April 30, 2009		49,250			49,250
Additional paid-in capital		1,337,055			1,337,055
Translation adjustment		14,804			10,297
Deficit		(1,459,605	)		(893,028	)
Total stockholders' equity (deficit)		(58,496	)		503,574
Total liabilities and stockholders' equity	$	184,294		$	520,337

The accompanying notes are an integral part of these consolidated financial statements.

3

ENHANCE SKIN PRODUCTS INC.
formerly Zeezoo Software Corp.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
For the three months and nine months ending January 31, 2010, and January 31, 2009
(Unaudited)
	Three Months						Nine Months
	ended						ended
	January 31						January 31
	2010			2009			2010			2009
Revenue	$	340		$	-		$	1,151		$	-
Cost of goods sold		37			-			192			-
Gross profit		303			-			959			-
EXPENSES
Operating expenses
General & administrative		155,164			129,599			409,946			267,504
Professional fees		13,396			28,535			59,160			55,683
Marketing		20,408			37,765			98,774			161,290
		188,968			195,899			567,880			484,477
Net loss before other items		(188,665	)		(195,899	)		(566,921	)		(484,477	)
Other items
Interest on long term debt		-			-			-			628
Interest income		(3	)		(914	)		(344	)		(3,238	)
Net loss before income taxes		(188,662	)		(194,985	)		(566,577	)		(481,867	)
Provision for income taxes		-			-			-			-
Net loss	$	(188,662	)	$	(194,985	)	$	(566,577	)	$	(481,867	)
Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.02	)
Weighted average number of common
shares outstanding		49,250,000			42,290,762			49,250,000			30,513,591

 

The accompanying notes are an integral part of these consolidated financial statements.

4

ENHANCE SKIN PRODUCTS INC.
formerly Zeezoo Software Corp.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
For the nine months ending January 31, 2010 and the year ending April 30, 2009
(Unaudited)
							Additional									Total
	Common Stock						paid in			Translation						Stockholders
	Shares			Amount			Capital			Adjustment			Deficit			Equity
Balance April 30, 2008		10			90			222,687			(3,741	)		(207,809	)		11,227
Asset Purchase Agreement
executed August 14, 2008
Shares assumed		20,250,000			20,250			(20,250	)								-
Shares issued		27,500,000			27,500			(27,500	)								-
Shares cancelled		(10	)		(90	)		90									-
Private placement closed
August 14, 2008 @ $1.00		1,500,000			1,500			1,153,900									1,155,400
Contribution to APIC								10,749									10,749
Net liabilities acquired from Zeezoo								(2,621	)								(2,621	)
Increase in translation adjustment											14,038						14,038
Net loss for the  period														(685,219	)		(685,219	)
Balance April 30, 2009		49,250,000		$	49,250		$	1,337,055		$	10,297		$	(893,028	)	$	503,574
Increase in translation adjustment											4,507						4,507
Net loss for the  period														(566,577	)		(566,577	)
Balance January 31, 2010		49,250,000		$	49,250		$	1,337,055		$	14,804		$	(1,459,605	)	$	(58,496	)

The accompanying notes are an integral part of these consolidated financial statements.

5

ENHANCE SKIN PRODUCTS INC.
formerly Zeezoo Software Corp.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
For the three months and nine months ending January 31, 2010, and January 31, 2009
(Unaudited)
	Nine Months
	ended
	January 31
	2010			2009
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(566,577	)	$	(481,867	)
Changes in operating assets and liabilities:
Accounts receivable		(140	)		-
Sales tax recoverable		7,478			(7,676	)
Prepaids & deposits		18,107			(13,342	)
Inventory		(35,640	)		(16,874	)
Accounts payable and accrued liabilities		68,222			22,878
Accounts payable to related party		139,101			977
Cash flows from operating activities		(369,449	)		(495,904	)
CASH FLOWS FROM INVESTING ACTIVITIES
Patent applications		(9,507	)		63
Trademarks		(938	)		2,280
Cash flows from investing activities		(10,445	)		2,343
CASH FLOWS FROM FINANCING ACTIVITIES
Procceds from issuance of common stock		-			1,155,400
Proceeds from related party advances		18,704			-
Increase in additional paid in Capital		-			10,749
Net liabilities acquired from Zeezoo		-			(2,621	)
Payment of loans		-			(41,161	)
Cash flows from financing activities		18,704			1,122,367
NET INCREASE (DECREASE) IN CASH		(361,190	)		628,806
Effect of foreign currency translation adjustments		4,507			9,548
Cash, beginning of the period		361,606			(3,088	)
Cash, end of the period	$	4,923		$	635,266
Supplemental disclosure with respect to cash flows:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	628

The accompanying notes are an integral part of these consolidated financial statements.

6

ENHANCE SKIN PRODUCTS INC.

formerly Zeezoo Software Corp.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

January 31, 2010

(unaudited)

NOTE 1.   BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial statements. Accordingly, our interim statements do not include all of the information and disclosures required for our annual financial statements. In the opinion of our management, the consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of these interim results. These consolidated financial statements should be read in conjunction with our consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended April 30, 2009. The results f or the nine months ended January 31, 2010 are not necessarily indicative of the results that may be expected for the full year ending April 30, 2010.

In May 2009, the Financial Accounting Standards Board (“FASB”) issued accounting guidance, effective for financial statements issued for interim and annual periods ending after June 15, 2009, which requires us to disclose the date through which we have evaluated subsequent events and whether the date corresponds with the release of our financial statements.  We have evaluated subsequent events through March 16, 2010, the date the financial statements were available to be issued.

Recently Adopted Accounting Standards

Sales return policy.  The Company will accept returns for damaged goods only, the goods must be returned unused and in the original packaging.  Sales are recorded when products are shipped to customers.  To date there have been only 5 sales with no returns or allowances.  The Company is presently determining an appropriate provision for returns and allowances which will be applied on future sales.

Effective July 1, 2009, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 105-10, “Generally Accepted Accounting Principles.” ASC 105-10 establishes the FASB Accounting Standards Codification™ (“Codification”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP for SEC registrants. All guidance contained in the Codification carries an equal level of authority. The Codification supersedes all existing non-SEC accounting and reporting standards. The FASB will now issue new standards in the form of Accounting Standards Updates (“ASUs”). The FASB will not consider ASUs as authoritative in their own right. ASUs will serve only to update the Codification, provide background information about the guidance and provide the bases for conclusions on the changes in the Codification. References made to FASB guidance have been updated for the Codification throughout this document.

NOTE 2.   GENERAL ORGANIZATION AND BUSINESS

Enhance Skin Products Inc. (formerly Zeezoo Software Corp.) was originally incorporated under the laws of the state of Nevada on November 14, 2006.  

Pursuant to an Asset Purchase Agreement by and between the Company and Enhance Private which closed on August 14, 2008, the Company acquired the Assets of Enhance Private. In addition to shares issued for the asset purchase and the cancellation of certain securities of the Company, Enhance Private has acquired approximately 57.6% of the Common Stock of the Company.  On August 28, 2008 the Company changed its name to Enhance Skin Products Inc.

7

For accounting purposes, this transaction was treated as an acquisition of Zeezoo Software Corp. and a recapitalization of Enhance Skin Products Inc.  Enhance Private is the accounting acquirer and the results of its operations carryover. Accordingly, the operations of Zeezoo Software Corp are not carried over and will be adjusted to $0.  Immediately prior to the Merger, Zeezoo Software Corp had minimal assets and liabilities.

The financial statements are presented based on this recapitalization, whereby the Company has 49,250,000 common shares outstanding as of August 14, 2008.

The Company is now a developer of premium cosmeceutical products marketed under its “Visible Youth™” trademark. Cosmeceuticals are topically applied products containing ingredients that influence the biological function of skin and can be described as a marriage between cosmetics and pharmaceuticals. These products may improve the appearance and condition of the skin by delivering nutrients or protectants necessary for healthy skin.

These consolidated financial statements contain the consolidated accounts of the Company and its wholly owned subsidiary Enhance Skin Products (Canada) Limited.  All material inter-company accounts and transactions have been eliminated on consolidation.

NOTE 3.   GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown, and these financial statements do not give effect to adjustments that would be necessary to the carrying value and classification of assets and liabilities should the Company be unable to continue as a going concern.  The Company has net losses for the nine months ended January 31, 2010 of $566,577. The Company intends to fund operations through working capital and sales, which may be insufficient to fund its expenditures, working capital and other cash requirements for the next 12 months.

The ability of the Company to become a profitable entity is dependent upon the Company’s successful efforts to generate sales and then attain profitable operations.  In response to these problems, management has planned the following actions:

● Management has manufactured products to generate sales. There can be no assurances,  however, that management’s expectations of future sales will be realized.

● Management is presently seeking financing in the form of an equity raise.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 4.   RELATED PARTY TRANSACTIONS AND BALANCES

Included is an amount due to a Director and officers of $158,064, which has no repayment terms, is unsecured and is non-interest bearing.

During the period ended January 31, 2010, the Company expensed monthly consulting fees of $12,500 to Biostrategies Consulting Group Inc., a private Ontario company wholly owned by the Company’s CEO who is also a Director.  In the nine months ended January 31, 2010 the Company accrued $112,500 for these fees.  At January 31, 2010 the Company owed the CEO $63,125 in regards to these fees, another $68,800 was owed to other officers for their monthly fees.  In addition the Company owes the officers directors $7,435 for unreimbursed expenses.  The CEO also made a cash advance to the Company of $18,704.

8

The CEO, Director made contributions to additional paid capital of $0 and $10,749 in the nine months ended January 31, 2010 and January 31, 2009 respectively.

NOTE 5.   INVENTORY

During the nine months ended January 31, 2010 the  Company manufactured the complete product line and made them available for sale.  Inventory on the balance sheet consists of raw material and finished goods.  The breakdown is as follows:

	January 31		April 30
	2010		2009
Raw material	$	43,798	$	43,613
Finished goods		35,455		0
	$	79,253	$	43,613

NOTE 6.   OPERATING LEASES AND OTHER COMMITMENTS

The Company currently has a monthly lease commitment of $833 expiring October 31, 2011.

Fiscal	Lease
Year	Agreement		Total
2010	$	2,499	$	2,499
2011		9,996		9,996
2012		4,998		4,998
2013		0		0
2014		0		0
Total	$	17,493	$	17,493

NOTE 7.   SUBSEQUENT EVENTS

1.  On February 23, 2010 the Company received invoices in the total amount of £210,000 from Mercuriali Ltd. (the “Mercuriali Claim”), a company controlled by Donald Nicholson, a director of the Company.  Mercuriali alleges that the Mercuriali Claim is due under the terms of a Letter of Intent between the Company and Mercuriali regarding a proposed merger between the Company and Mercuriali as part of a larger transaction involving the reverse merger of the Company into a company listed on AIM, a sub-market of the London Stock Exchange.  Neither the merger between Mercuriali and the Company, nor the reverse merger of the Company and the AIM listed company took place.  The Company believes that the amounts claimed by Mercuriali are without merit and intends to seek an amicable resolution of the matter.  There can be no assur ances that the Company and Mercuriali will be able to reach an amicable resolution with respect to the Mercuriali Claim.

2. The CEO Director made additional cash advances to the Company of $1,400 on February 17, 2010 and $23,380 on February 19, 2010.

9

ITEM 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following selected comparative financial information has been derived from and should be read in conjunction with the financial statements of the Company for the year ended April 30, 2009.

	3 Months ended							9 Months ended
	January 31, 2010							January 31, 2010
		2010			2009			2010			2009
Total Sales		$	340		$	-		$	1,151		$	-
Cost of goods sold			37			-			192			-
Gross profit			303			-			959			-
Operating expenses			188,968			195,899			567,880			484,477
Net loss befor other items			(188,665	)		(195,899	)		(566,921	)		(484,477	)
Other items
Interest on long term debt			-			-			-			628
Interest income			(3	)		(914	)		(344	)		(3,238	)
Net loss		$	(188,662	)	$	(194,985	)	$	(566,577	)	$	(481,867	)
Net loss per share (1)		$	-		$	-		$	(0.01	)	$	(0.02	)
(1) less than $0.01								January 31			April 30
									2010			2009
Total assets								$	184,294		$	520,337

Sales

During nine months ended January 31, 2010 the Company recorded $1,151 of sales.  The gross profit on these sales was $959 or 83.3%.  Included in sales are the freight charges to the customer to ship the product.  During the quarter ended January 31, 2010 the Company recorded $340 of sales with a gross profit of $303 or 89%.  The gross profit in the quarter was greater as a percentage than the year to date gross profit, as the sales in this quarter were at retail prices, resulting in greater gross profit.  The Company did not record any sales in the three months and nine months ended January 31, 2009.  The Company is currently examining alternative marketing plans to accelerate sales.

Cost of goods sold

The cost of the sales for the three months and nine months ended January 31, 2010 were $37 and $192, respectively.  Included in the cost of goods sold are direct manufacturing costs, including materials and packaging.  Also, included in cost of goods sold are the direct costs to package and ship the product.

Operating Expenses

Our operating expenses are classified primarily into the following categories.

General and administrative

General & administrative expenses for the nine months ended January 31, 2010 were $409,946 or $142,442 more than the $267,504 recorded in the same period ended January 31, 2009.  This increase of 53% is mainly attributed to the fact the Company was not operational for the first four months of the period ended January 31, 2009.   Of the $409,946 of general and administrative expenses incurred in the nine months ended January 31, 2010, salaries contributed to 88.5% or $362,598, travel was 4.2% or $17,175, rent was 3.1% or $12,628, office was 1.9% or 7,710, the balance of  $9,835 or 2.4% was made up of bank charges, foreign exchange losses and corporate charges.

10

General and administrative expenses for the three months ended January 31, 2010 were $155,164 or $25,565 more than the $129,599 recorded in the three months ended January 31, 2009.  The reason for the increase in the current quarter is due to increased remuneration during the quarter ended January 31, 2010.

Professional fees

Professional fees for the nine months ended January 31, 2010 were $59,160 or $3,477 more than the $55,683 recorded in the same period ended January 31, 2009.  In the nine months ended January 31, 2010 legal fees was the largest contributor to professional fees at $33,006 or 55.8% of total professional fees, fees to the Company’s auditor were  $19,540 or 33%, and fees to other consultants were $6,614 or 11.2%.  

Professional fees for the three months ended January 31, 2010 were $13,396 or $15,139 less than the $28,535 recorded in the same quarter ended January 31, 2009.  In the three months ended January 31, 2010 legal fees was the largest contributor to professional fees at $7,472 or 55.8% of total professional fees, fees to the Company’s auditor were  $3,500 or 26.1% and fees to other consultants were $2,424 or 18.1%.  The reason for the decrease in the current quarter compared to the three months ended January 31, 2009 was due to high fees to the Company’s auditors in the quarter ended January 31, 2009, as a result of the additional work required for the reverse merger and financing in August of 2008.

Marketing

Marketing expenses for the nine months ended January 31, 2010 were $98,774 or $62,516 less than the $161,290 recorded in the nine months ended January 31, 2009.  In the nine months ended January 31, 2009 the Company incurred the cost of designing the Company’s logo and product packaging as well as developing the Company’s marketing material.  These costs were not repeated in the nine months ended January 31, 2010, thus the decrease in marketing expenses from the nine months ended January 31, 2009.  Included in the marketing expenses of $98,774 in the nine months ended January 31, 2010 were web site development costs of $50,982 or 51.6% of the total marketing expenses.  Other expenses were trade shows of $11,787 or 11.9%, travel of $10,514 or 10.6%, marketing consultant fees of $10,000 or 10.1%, advertising of $8,335 or 8.4%, clinical research of $6,459 or 6.5% and warehousing the Company’s inventory of $697 or .7%.

Marketing expenses for the three months ended January 31, 2010 were $20,408 or $17,357 less than the $37,765 recorded in the three months ended January 31, 2009.  The decrease in the current quarter is a result of decreased costs for the development of the Company’s web site, as well as decreased travel.  Included in the marketing expenses of $20,408 for the three months ended January 31, 2010 were web site development costs of $2,520 or 12.3% of the total marketing expenses.  Other expenses were trade shows and travel of $551 or 2.7%, marketing consultant fees of $10,000 or 49%, clinical research $6,459 or 31.6%, advertising of $453 or 2.2% and warehousing the Company’s inventory of $425 or 2.1%.

Other Items

Interest on long term debt decreased by $628 in the nine months ended January 31, 2010 from the 2009 expense of $628.  The debt was paid in August 2008 after the equity financing was received.

As the Company had cash on hand after the equity financing of August 14, 2009, the Company earned interest income on the surplus funds.  In the nine months ended January 31, 2010 the Company earned $344 of interest income compared to $3,238 earned in the nine months ended January 31, 2009.  The decrease can be attributed to the decrease in surplus funds in the nine months ended January 31, 2010.  

Interest of $3 was earned in the quarter ended January 31, 2010, which was $911 below the interest earned of $914 in the quarter ended January 31, 2009.  The decrease in the quarter was a result of the Company not having surplus funds.

11

Liquidity and Capital Resources

At the end of the nine months ending January 31, 2010, the Company had working capital deficit of $123,293, as compared to the working capital of $416,293 at the year ended April 30, 2009.  The decrease of $539,586 is attributed entirely to the operating expenses of the nine months ended January 31, 2010.

At nine months ended January 31, 2010 the total assets were $184,294 as compared to the total assets $520,337 at April 30, 2009.  The decrease in total assets of $336,043 coincides with the decrease in working capital after adjusting for the increase in accounts payable.

The complete line of the Company’s products was manufactured in the quarter ended July 31, 2009.  The Company had relied on the financing of August 2008 for its working capital requirements until the end of the fiscal third quarter ended January 31, 2010.  In the second quarter of fiscal 2010 ended October 31, 2010 the Company launched its new complete line of skin care products.  The Company was expecting the gross profit on sales to fulfill its working capital requirements; however, sales have been disappointing.  The Company has hired an independent marketing consultant to develop and revise the Company’s marketing strategy.  The Company is, also, seeking further financing to fund operations until the Company has sales sufficient to fund its operations.    
60; 

ITEM 3.   Quantitative and Qualitative Disclosures About Market Risk.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices. Our primary exposure to market risk is interest rate risk associated with our short term money market investments. The Company does not have any financial instruments held for trading or other speculative purposes and does not invest in derivative financial instruments, interest rate swaps or other investments that alter interest rate exposure. The Company does not have any credit facilities with variable interest rates.

ITEM 4T.   Controls and Procedures.

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on their evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures are effective in giving us reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likeliho od of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

12

Changes in Internal Control Over Financial Reporting

In our Management’s Report on Internal Control Over Financial Reporting included in the Company’s Form 10-K/A for the year ended April 30, 2009, management concluded that our internal control over financial reporting was effective as of April 30, 2009.

Our management did, however, identify a significant deficiency; a significant deficiency is a deficiency, or a combination of deficiencies, that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of our financial reporting.  Currently, we do not have sufficient in-house expertise in US GAAP reporting.  Instead, we rely very much on the expertise and knowledge of external financial advisors in US GAAP conversion.  External financial advisors have helped prepare and review our consolidated financial statements.  Although we have not identified any material errors with our financial reporting or any material weaknesses with our internal controls, no assurances can be given that there are no such material errors or weaknesses existing. 0; To remediate this situation, we are seeking to recruit experienced professionals to augment and upgrade our financial staff to address issues of timeliness and completeness in US GAAP financial reporting.  In addition, we do not believe we have sufficient documentation with our existing financial processes, risk assessment and internal controls.  We plan to work closely with external financial advisors to document the existing financial processes, risk assessment and internal controls systematically.

We believe that the remediation measures we are taking, if effectively implemented and maintained, will remediate the significant deficiency discussed above.

Except as described above, there have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

PART II - OTHER INFORMATION

ITEM 1.   Legal Proceedings.

We are not aware of any material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we [or any of its subsidiaries] are a party or of which any of our property is subject. We are not aware of any legal proceedings in which any of our directors or officers, any of our proposed directors or officers or any owner of record or beneficial owner of more than 5% of any class of our voting securities, or any affiliate of any such director or officer, proposed director or officer or security holder, is a party adverse to us or has a material interest adverse to our company.

ITEM 2.   Unregistered Sales of Equity Securities and Use of Proceeds.

None.

ITEM 3.   Defaults Upon Senior Securities.

None.

ITEM 4.   Submission of Matters To a Vote of Security Holders.

None.

13

ITEM 5.   Other Information.

None

ITEM 6.   Exhibits.

(a)   Pursuant to rule 601 of Regulation  S-K, the following  exhibits are included herein or incorporated by reference.

Exhibit Number	Description
31.1	Certification  of CEO Pursuant TO 18 U.S.C. § 1350, Section 302
31.2	Certification  of CFO Pursuant to 18 U.S.C. § 1350, Section 302
32.1	Certification Pursuant to 18 U.S.C. § 1350, Section 906
32.2	Certification Pursuant to 18 U.S.C. § 1350, Section 906

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 17th day of March, 2010.

	ENHANCE SKIN PRODUCTS INC.
Date:  March 17, 2010	By:	/s/ Dr. Samuel S. Asculai
		Name:  Dr. Samuel S. Asculai
		Title:    President/CEO, Principal Executive Officer

Date:  March 17, 2010	By:	/s/ Brian Lukian
		Name:  Brian Lukian
		Title:    Chief Financial Officer, Principal Financial Officer

14